What Retina Specialists Have Learned From TRUCKEE

Carl J. Danzig, MD, reviews 4.5 years of real-world findings showing sustained anatomic improvements, longer treatment intervals, and a favorable safety profile with faricimab in neovascular AMD.

By
Carl Danzig, MD
July 15, 2026
3 min

Retinal Physician

At a Glance

Category	Detail
Condition	Neovascular Age-Related Macular Degeneration (nAMD)
Key Mechanisms	Faricimab demonstrates sustained anatomic improvements and longer treatment intervals.
Target Population	Patients with neovascular AMD, including treatment-naïve and previously treated individuals.
Care Setting	Real-world clinical practice

Key Highlights

Faricimab shows rapid improvement in anatomic parameters over 4.5 years.
Treatment-naïve patients achieved treatment intervals of up to 10 weeks.
Low rates of intraocular inflammation and endophthalmitis were reported.
Patients switching from aflibercept experienced nearly 2-week interval extension after 9 injections.
The study involved over 3,600 eyes and 2,900 patients.

Guideline-Based Recommendations

Diagnosis

Monitor central subfield thickness, pigment epithelial detachment, subretinal fluid, and intraretinal fluid.

Management

Consider faricimab for both treatment-naïve and previously treated patients.

Monitoring & Follow-up

Assess for intraocular inflammation and other adverse events.

Risks

Monitor for potential adverse events such as bilateral nonocclusive vasculitis.

Patient & Prescribing Data

Patients with neovascular AMD, including those who are treatment-naïve and those previously treated.

Faricimab allows for extended treatment intervals with continued anatomical improvement.

Clinical Best Practices

Evolve treatment intervals based on patient response and comfort level with faricimab.
Utilize faricimab in real-world settings to optimize patient outcomes.